Lukang Pharmaceutical (600789.SH) obtained registration approval for imatinib mesylate tablets and APIs

Zhitongcaijing · 1d ago

Zhitong Finance App News, Lukang Pharmaceutical (600789.SH) issued an announcement. Recently, the company received the “Drug Registration Certificate” for imatinib mesylate tablets and the “Chemical Ingredient Application Approval Notice” for imatinib mesylate tablets and the “Chemical Ingredient Application Approval Notice” for imatinib mesylate APIs. The approval of imatinib mesylate tablets and APIs has enriched the company's formulation and API product line, providing effective help for the company to improve its market competitiveness.

According to reports, imatinib is a protein tyrosine kinase inhibitor that can strongly inhibit abelson (BCR-ABL) tyrosine kinase in the breakpoint cluster region at the cellular level both in vivo and abroad. The drug selectively inhibits the proliferation and induces apoptosis of BCR-ABL-positive cell line cells and fresh leukemia cells in Philadelphia chromosome-positive CML and acute lymphocytic leukemia (ALL) patients. It can also inhibit platelet-derived growth factor (PDGF) receptor, stem cell factor (SGF), and KIT receptor tyrosine kinase, thereby inhibiting PDGF and SCF mediated cellular behavior.